Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort - Top-Institutions - MDSpire

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

  • By

  • Augustin Boudry

  • Laurène Fenwarth

  • Raphaël Itzykson

  • Thorsten Braun

  • Lionel Adès

  • Élise Fournier

  • Céline Berthon

  • Delphine Lebon

  • Stéphane De Botton

  • Régis Peffault de Latour

  • Cécile Pautas

  • Hervé Dombret

  • Emmanuel Raffoux

  • Claude Gardin

  • Karine Celli-Lebras

  • Claude Preudhomme

  • Nicolas Duployez

  • May 28, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    ALFA-1200 cohort
    ALFA-1200 cohort

    N/A, N/A

    Key Differentiators

    • Hematology

  • #2

    ECOG-ACRIN Cancer Research Group
    ECOG-ACRIN Cancer Research Group

    N/A, N/A

    Key Differentiators

    • Hematology

  • #3

    University of Maryland School of Medicine
    University of Maryland School of Medicine

    Baltimore, MD

    Key Differentiators

    • Hematology

  • #4

    Center for International Blood and Marrow Transplant Research
    Center for International Blood and Marrow Transplant Research

    N/A, N/A

    Key Differentiators

    • Hematology

  • #5

    Spanish CETLAM group
    Spanish CETLAM group

    N/A, N/A

    Key Differentiators

    • Hematology

Original Source(s)

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

  • by Augustin Boudry, Laurène Fenwarth, Raphaël Itzykson, Thorsten Braun, Lionel Adès, Élise Fournier, Céline Berthon, Delphine Lebon, Stéphane De Botton, Régis Peffault de Latour, Cécile Pautas, Hervé Dombret, Emmanuel Raffoux, Claude Gardin, Karine Celli-Lebras, Claude Preudhomme, Nicolas Duployez

  • May 28, 2026

Related Content

Case Report: First description of an intracranial “NET” in ROHHAD syndrome; time to rename to the ROHHAD-NeCT syndrome?

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report